Haemophilia and Aids

Bird, A. G.; Codd, A. A.; Collins, Abigail M

doi:10.1016/s0140-6736(85)91929-4

Cited by 17 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there were earlier proponents of the idea that heating the concentrates should be effective against AIDS, particularly the late Harold Roberts, in 1983 and 1984 there was little evidence that heat treatment would be efficacious against the putative viral agent. In addition, there were concerns about the potential denaturation induced by heating of a labile protein such as FVIII, and the possibility of increased production of antibodies (inhibitors) against FVIII . Furthermore, the failure of the early methods based on dry heating to inactivate the hepatitis virus was a fundamental snag, because it convinced many of us that the method had, in general, little virucidal activity.…”

Section: Hiv Infection and Aidsmentioning

confidence: 99%

Viral safety of coagulation factor concentrates: memoirs from an insider

Mannucci

2018

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

The purpose of this essay is to recall the actions taken globally to improve the viral safety of coagulation factor concentrates, mainly in the years 1985-1990, at a time of confusing and often contradictory information on bloodborne viral infections in multitransfused patients with hemophilia (PWHs). I shall first recall the problem of the transmission and control of the hepatitis viruses, and then that of HIV: not only for temporal reasons, but also because understanding the progress of knowledge on hepatitis and the poor success of the early measures taken to tackle this problem in PWHs is essential to understand how the problem of HIV transmission was ultimately dealt with successfully.

show abstract

Section: Hiv Infection and Aidsmentioning

confidence: 99%

Viral safety of coagulation factor concentrates: memoirs from an insider

Mannucci

2018

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…In 1983 and early 1984 there was little reason to believe that a heating procedure that was incapable of inactivating the hepatitis viruses, in particular the virus causing non‐A, non‐B hepatitis [20], should be more efficacious against the putative viral agent causing AIDS. Moreover, there were concerns about the potential risk of denaturation induced by heating on a labile protein such as FVIII and about the possibility of increased production of antibodies (inhibitors) to FVIII [31], with the view that drastic changes in the manufacturing process, such as those induced by heating, could affect the shape of the molecule and result in denaturation and neoantigenicity [31].…”

Section: Hiv Infection and Aidsmentioning

confidence: 99%

AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider

2003

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

“…The heat ing protocol included heating for 96 h at 68 °C, a temper ature exposure more than adequate for inactivation of HIV [29,40] and effective in reducing NANB infectivity in factor VIII concentrates [41]. Although the stability of Cl-INA was similar in both the intermediate-and highpurity concentrates, contaminants in the former suggest a potential risk of neo antigenicity [42,43]. Therefore, the high-purity concentrate is more suitable for heat treat ment, is 5 times more pure and in contrast to the prepa ration described by Vogelaar et al [32] contains only traces of ceruloplasmin with no detectable C4 comple ment component.…”

Section: Heat Treatmentmentioning

confidence: 99%

Heat Stability of Lyophilized C1 Inactivator Concentrates

Wickerhauser¹,

Williams²,

Kolen³

et al. 1987

Vox Sanguinis

View full text Add to dashboard Cite

Heat stability of lyophilized Cl inactivator (Cl-INA) concentrates of intermediate and high purity has been investigated under several heat treatment protocols that include heating for 96 and 192 h at 68 °C and for 10 h at 80, 90 and 100°C. Both types of concentrate showed high stability in functional activity, with not more than 5% loss in any of the time-temperature combinations evaluated. However, the C1-INA antigen from both concentrates showed small but progressive changes in crossed immunoelectrophoretic pattern, in proportion to the intensity of heat treatment. High-pressure size-exclusion chromatography revealed only minimal signs of aggregation in the high-purity concentrate, but a significant and progressive aggregation of nonspecific protein contaminants present in the intermediate-purity concentrate, making the high-purity concentrate preferable for heat treatment

show abstract

Haemophilia and Aids

Cited by 17 publications

References 3 publications

Viral safety of coagulation factor concentrates: memoirs from an insider

Viral safety of coagulation factor concentrates: memoirs from an insider

AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider

Heat Stability of Lyophilized C1 Inactivator Concentrates

Contact Info

Product

Resources

About